Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.
Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.
This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced the granting of restricted stock units (RSUs) to 42 new employees under its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grant on October 1, 2024, for an aggregate of 364,000 shares of common stock.
These RSUs are designed as an inducement for new hires, in compliance with NASDAQ Listing Rule 5635(c)(4). The grants will vest over three years in equal annual installments, contingent on continued employment with Xeris or its subsidiaries. All awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and relevant award agreements.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced its participation in three upcoming investor conferences in September 2024. The company will attend the 2024 Wells Fargo Healthcare Conference in Boston on September 4 for meetings only. At the H.C. Wainwright 26th Annual Global Investor Conference in New York on September 10, Xeris will participate in meetings and a fireside chat at 3:30pm ET. Lastly, the company will be present at the 2024 Cantor Global Healthcare Conference in New York on September 18 for meetings only.
Investors interested in 1x1 meetings should contact the conference sponsors directly. A webcast of the fireside chat will be available on Xeris' investor relations website. This participation in multiple conferences demonstrates Xeris' commitment to engaging with investors and showcasing its growth-oriented biopharmaceutical business.
Xeris Biopharma (Nasdaq: XERS) reported strong Q2 2024 financial results, with total revenue of $48.1M, including record product revenue of $46.5M. This represents an 18% increase over the prior quarter and a 26% increase year-over-year. The company tightened its full-year 2024 guidance, projecting total net revenue of $190M-$200M and a year-end cash balance of $60M-$75M.
Key highlights include:
- Gvoke revenue up 28% to $20.0M
- Recorlev revenue up 86% to $13.3M
- Keveyis revenue down 7% to $13.1M due to generic competition
- Cash position of $77.6M as of June 30, 2024
- Net loss of $15.0M for Q2 2024
The company also announced leadership changes, with John Shannon appointed as CEO and Kevin McCulloch promoted to President and COO.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced that it will release its second quarter 2023 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss its financial and operational results.
Interested parties can pre-register for the call using the provided link. A replay of the conference call will be available until Thursday, August 22, 2024. The webcast can be accessed through the 'Events' section on the company's investor relations page or via the provided link.
Xeris Biopharma has announced a CEO succession plan effective August 1, 2024. John Shannon, the company's current President and COO, will succeed Paul Edick as CEO and join the Board of Directors. Edick will continue in a senior advisory role until February 1, 2026. Marla S. Persky will become the new Chairperson of the Board.
The timing aligns with Xeris' strong financial performance, including anticipated Q2 2024 revenue exceeding $47 million, marking over 23% growth from the previous year. The company reaffirms its year-end 2024 cash guidance to be between $55 million and $75 million. Shannon brings over 40 years of experience in the pharmaceutical and healthcare industry to his new role.
Xeris Biopharma Holdings (Nasdaq: XERS) announced the granting of restricted stock units (RSUs) for 196,000 shares of its common stock to 26 new employees. These grants, under the NASDAQ Rule 5635(c)(4), were made on July 1, 2024, as part of Xeris' Inducement Equity Plan. The RSUs will vest over three years, contingent on continued employment. This plan aims to attract new talent to the organization.
Xeris Biopharma Holdings (Nasdaq: XERS) presented a post-hoc analysis from the SONICS study at ENDO 2024 in Boston (June 1-4, 2024). The analysis focused on the effects of levoketoconazole (Recorlev®) in Cushing’s syndrome patients. Key findings include a higher cortisol normalization rate in patients with lower baseline mUFC, who also required lower doses of Recorlev and experienced fewer liver-related adverse events. Group 2, with intermediate baseline mUFC, showed the highest mUFC response rate (36.4%), while Group 3 had the highest average daily dose and more liver-related adverse events. These findings highlight the importance of individualizing medical management based on baseline mUFC levels.
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug than daily oral doses. Participants reported higher satisfaction and a strong preference for the SC route. The FDA End-of-Phase 2 interaction is expected by year-end, aiming for a Phase 3 pivotal study. Adverse events were mostly mild, with no serious adverse events reported.
Xeris Biopharma Holdings (Nasdaq: XERS) announced its participation in the Jefferies Global Healthcare Conference. Senior management will host a fireside chat on June 6 at 2:00 PM Eastern Time. A live webcast will be available on Xeris’ Investor Relations website and will remain accessible for 60 days.
Xeris Biopharma reported a Q1 2024 total revenue of $40.6M, up 22% from Q1 2023, with full-year 2024 revenue guidance set at $175M-$200M. They ended Q1 with $87.4M in cash, closed licensing agreements for XeriJect® and XeriSol™ formulations, and announced a partnership with Beta Bionics. The company highlighted growth in product revenue, net revenue, and new technology partnerships.
FAQ
What is the current stock price of Xeris Biopharma Holdings (XERS)?
What is the market cap of Xeris Biopharma Holdings (XERS)?
